RESUMO
OBJECTIVE: Familial dysautonomia (FD) is a rare inherited autosomal recessive disorder with abnormal somatosensory, enteric, and afferent autonomic neurons. We aimed to define the incidence of gastrointestinal bleeding and its associated risk factors in patients with FD. METHODS: In this retrospective case-control study, we identified all episodes of gastrointestinal bleeding in patients with FD, occurring over four decades (January 1980-December 2017), using the New York University FD registry. RESULTS: We identified 104 episodes of gastrointestinal bleeding occurring in 60 patients with FD. The estimated incidence rate of gastrointestinal bleeds in the FD population rate was 4.20 episodes per 1000 person-years. We compared the 60 cases with 94 age-matched controls. Bleeding in the upper gastrointestinal tract from gastric and duodenal ulcers occurred most frequently (64 bleeds, 75.6%). Patients were more likely to have a gastrostomy (G)-tube and a Nissen fundoplication [odds ratio (OR) 3.73, 95% confidence interval (CI) 1.303-13.565] than controls. The mean time from G-tube placement to first gastrointestinal bleed was 7.01 years. The mean time from Nissen fundoplication to bleed was 7.01 years. Cases and controls had similar frequency of intake of nonsteroidal antiinflammatory drugs (NSAID) and selective serotonin reuptake inhibitors (SSRI). CONCLUSION: The incidence of gastrointestinal bleeding in the pediatric FD population was estimated to be 4.20 per 1000 person-years, 21 times higher than in the general pediatric population (0.2 per 1000 person-years). Patients with FD with a G-tube and a Nissen fundoplication had a higher risk of a subsequent gastrointestinal bleeding.
Assuntos
Disautonomia Familiar , Humanos , Criança , Disautonomia Familiar/complicações , Disautonomia Familiar/epidemiologia , Estudos de Casos e Controles , Estudos Retrospectivos , Hemorragia Gastrointestinal/etiologia , Hemorragia Gastrointestinal/complicações , Inibidores Seletivos de Recaptação de SerotoninaRESUMO
PURPOSE: Patients with the autosomal recessive disorder of familial dysautonomia typically exhibit exacerbated adverse side effects to many common drugs. We aimed to catalog these adverse effects - with a focus on common drugs that are frequently administered to FD patients and compare their incidences to those within the general population. METHODS: We used data of 595 FD patients from an international database with information on drugs received and adverse effects. To investigate the molecular causes of reported differences in drug responses in FD patients, we used expression microarrays to compare the mRNA expression profiles in peripheral blood leukocytes of FD patients (n = 12) and healthy individuals (n = 10). RESULTS: Several drug classes, including cholinergics, anti-cholinergics, anti-convulsants, methylxanthines, SSRIs, and antibiotics caused either unreported symptoms or elevated rates of adverse events in FD patients. FD patients experienced different or more frequent adverse side effects than the general population in 31/123 drugs. These side effects included blood cell dyscrasias, amenorrhea, gastrointestinal bleeding, and bronchospasm. New findings include enhanced reaction of FD patients to H2 antagonist agents and to serotonin receptor agonists. We also detected eight genes differentially expressed between FD patients and healthy individuals that may underlie the differential drug responses of FD patients. CONCLUSION: We provide evidence that suggests the use of several common drugs should be discontinued or reduced in FD patients.
Assuntos
Disautonomia Familiar , Preparações Farmacêuticas , Proteínas de Transporte , Disautonomia Familiar/epidemiologia , Disautonomia Familiar/genética , Feminino , Humanos , Fatores de Elongação da TranscriçãoRESUMO
PURPOSE: Familial dysautonomia (FD) is a rare hereditary sensory and autonomic neuropathy (HSAN-3) that is clinically characterized by impaired pain and temperature perception and abnormal autonomic function. Patients with FD have gastrointestinal dysmotility and report a range of gastrointestinal symptoms that have yet to be systematically evaluated. The aim of this study was to establish the frequency and severity of gastrointestinal symptoms in patients with FD. METHODS: The validated National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) survey questionnaire, together with additional FD-specific questions, were distributed to 202 living patients with genetically confirmed FD who had been identified from the New York University FD Patient Registry or, when relevant, to their respective caretaker. As a comparison group, we used a general US adult population for whom PROMIS scores were available (N = 71,812). RESULTS: Of the 202 questionnaires distributed, 77 (38%) were returned, of which 53% were completed by the patient. Median age of the respondents was 25 years, and 44% were male. Gastrostomy tube was the sole nutrition route for 25% of the patients, while 53% were reliant on the gastrostomy tube only for liquid intake. The prevalence of gastrointestinal symptoms was significantly higher in each of the eight domains of PROMIS in patients with FD than in the controls. Gastrointestinal symptoms as measured by raw scores on the PROMIS scale were significantly less severe in the FD patient group than in the control population in all domains with the exception of the abdominal pain domain. The surveys completed by caregivers reported the same burden of symptoms as those completed only by patients. CONCLUSION: Gastrointestinal symptoms affect nearly all patients with FD. Gastrointestinal symptoms are more prevalent in adult patients with FD than in the average US adult population but are less severe in the former.
Assuntos
Disautonomia Familiar , Gastroenteropatias , Neuropatias Hereditárias Sensoriais e Autônomas , Adulto , Disautonomia Familiar/complicações , Disautonomia Familiar/epidemiologia , Gastroenteropatias/epidemiologia , Humanos , Masculino , Prevalência , Inquéritos e QuestionáriosRESUMO
BACKGROUND: Familial dysautonomia (Riley-Day syndrome, hereditary sensory autonomic neuropathy type-III) is a rare genetic disease caused by impaired development of sensory and afferent autonomic nerves. As a consequence, patients develop neurogenic dysphagia with frequent aspiration, chronic lung disease, and chemoreflex failure leading to severe sleep disordered breathing. The purpose of these guidelines is to provide recommendations for the diagnosis and treatment of respiratory disorders in familial dysautonomia. METHODS: We performed a systematic review to summarize the evidence related to our questions. When evidence was not sufficient, we used data from the New York University Familial Dysautonomia Patient Registry, a database containing ongoing prospective comprehensive clinical data from 670 cases. The evidence was summarized and discussed by a multidisciplinary panel of experts. Evidence-based and expert recommendations were then formulated, written, and graded using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) system. RESULTS: Recommendations were formulated for or against specific diagnostic tests and clinical interventions. Diagnostic tests reviewed included radiological evaluation, dysphagia evaluation, gastroesophageal evaluation, bronchoscopy and bronchoalveolar lavage, pulmonary function tests, laryngoscopy and polysomnography. Clinical interventions and therapies reviewed included prevention and management of aspiration, airway mucus clearance and chest physical therapy, viral respiratory infections, precautions during high altitude or air-flight travel, non-invasive ventilation during sleep, antibiotic therapy, steroid therapy, oxygen therapy, gastrostomy tube placement, Nissen fundoplication surgery, scoliosis surgery, tracheostomy and lung lobectomy. CONCLUSIONS: Expert recommendations for the diagnosis and management of respiratory disease in patients with familial dysautonomia are provided. Frequent reassessment and updating will be needed.
Assuntos
Consenso , Disautonomia Familiar/epidemiologia , Transtornos Respiratórios/epidemiologia , Transtornos Respiratórios/terapia , Lavagem Broncoalveolar/métodos , Broncoscopia/métodos , Síndrome de Brugada/epidemiologia , Transtornos de Deglutição/diagnóstico por imagem , Transtornos de Deglutição/fisiopatologia , Disautonomia Familiar/complicações , Disautonomia Familiar/mortalidade , Disautonomia Familiar/fisiopatologia , Prática Clínica Baseada em Evidências/métodos , Humanos , New York/epidemiologia , Pneumonia Aspirativa/diagnóstico por imagem , Pneumonia Aspirativa/fisiopatologia , Polissonografia/métodos , Estudos Prospectivos , Transtornos Respiratórios/diagnóstico por imagem , Transtornos Respiratórios/patologia , Testes de Função Respiratória/métodosRESUMO
OBJECTIVE: Adrenergic crises are a cardinal feature of familial dysautonomia (FD). Traditionally, adrenergic crises have been treated with the sympatholytic agent clonidine or with benzodiazepines, which can cause excessive sedation and respiratory depression. Dexmedetomidine is a centrally-acting α 2-adrenergic agonist with greater selectivity and shorter half-life than clonidine. We evaluated the preliminary effectiveness and safety of intravenous dexmedetomidine in the treatment of refractory adrenergic crisis in patients with FD. METHODS: Retrospective chart review of patients with genetically confirmed FD who received intravenous dexmedetomidine for refractory adrenergic crises. The primary outcome was preliminary effectiveness of dexmedetomidine defined as change in blood pressure (BP) and heart rate (HR) 1 h after the initiation of dexmedetomidine. Secondary outcomes included incidence of adverse events related to dexmedetomidine, hospital and intensive care unit (ICU) length of stay, and hemodynamic parameters 12 h after dexmedetomidine cessation. RESULTS: Nine patients over 14 admissions were included in the final analysis. At 1 h after the initiation of dexmedetomidine, systolic BP decreased from 160 ± 7 to 122 ± 7 mmHg (p = 0.0005), diastolic BP decreased from 103 ± 6 to 65 ± 8 (p = 0.0003), and HR decreased from 112 ± 4 to 100 ± 5 bpm (p = 0.0047). The median total adverse events during dexmedetomidine infusion was 1 per admission. Median hospital length of stay was 9 days [interquartile range (IQR) 3-11 days] and median ICU length of stay was 7 days (IQR 3-11 days). CONCLUSIONS: Intravenous dexmedetomidine is safe in patients with FD and appears to be effective to treat refractory adrenergic crisis. Dexmedetomidine may be considered in FD patients who do not respond to conventional clonidine and benzodiazepine pharmacotherapy.
Assuntos
Agonistas de Receptores Adrenérgicos alfa 2/administração & dosagem , Pressão Sanguínea/efeitos dos fármacos , Dexmedetomidina/administração & dosagem , Disautonomia Familiar/tratamento farmacológico , Frequência Cardíaca/efeitos dos fármacos , Administração Intravenosa , Adolescente , Adulto , Pressão Sanguínea/fisiologia , Disautonomia Familiar/epidemiologia , Disautonomia Familiar/fisiopatologia , Feminino , Frequência Cardíaca/fisiologia , Humanos , Hipertensão/tratamento farmacológico , Hipertensão/epidemiologia , Hipertensão/fisiopatologia , Tempo de Internação/tendências , Masculino , Estudos Retrospectivos , Taquicardia/tratamento farmacológico , Taquicardia/epidemiologia , Taquicardia/fisiopatologia , Adulto JovemRESUMO
Familial dysautonomia (FD) is a genetic disease characterized by primary autonomic dysfunction including parasympathetic hypersensitivity. Breath-holding spells (BHS) are believed to be caused by autonomic dysregulation mediated via the vagus nerve and increased in patients with a family history of BHS. Details and understanding of its pathophysiology are lacking. In this retrospective study of patients with FD, the incidence of BHS was higher at 53.3%, compared with previous studies in normal children. Laughter as a precipitating factor for BHS has not been previously reported in FD and occurred in 10% of patients in this study. Lower lung volumes, chronic lung disease, chronic CO2 retention, and inadequate autonomic compensation occur in those with FD leading to a higher incidence and severity of BHS when crying or laughing. Thus, FD may be a good model for understanding manifestations of the autonomic nervous system dysfunction and contribute to our knowledge of BHS mechanisms.
Assuntos
Suspensão da Respiração , Choro/fisiologia , Disautonomia Familiar/epidemiologia , Disautonomia Familiar/fisiopatologia , Riso/fisiologia , Criança , Pré-Escolar , Feminino , Humanos , Incidência , Lactente , Israel/epidemiologia , Masculino , Estudos Retrospectivos , Índice de Gravidade de DoençaRESUMO
BACKGROUND: Lung disease in patients with familia dysautonomia is caused mainly by recurrent aspiration of gastric contents, food and liquids swallowed incorrectly. OBJECTIVE: To describe chest computed tomography findings in patients with familial dysautonomia. METHODS: A retrospective analysis of chest CT findings was performed for 34 FD patients (15 females, 19 males) with a mean age of 18 +/- 12.8 years. RESULTS: The CT revealed bronchial wall thickening (in 94% of the patients), atelectasis (in 73%), ground glass opacities (in 53%), focal hyperinflation (in 44%), fibrosis (in 29%) and bronchiectasis (in 26%). The extrapulmonary abnormalities were scoliosis (79%) and esophageal dilatation (35%). Silent fractures were noted in two vertebral bodies and one rib. CONCLUSIONS: Pulmonary changes were consistent with chronic inflammation in the bronchi and interstitial tissues. Ground glass opacities and fibrosis support the theory that these changes could be due to gastric aspiration. Bronchiectasis is less frequent. Esophageal dilatation with fluid overflow adds to aspiration. Fractures can be asymptomatic and are often missed.
Assuntos
Disautonomia Familiar/diagnóstico por imagem , Pulmão/diagnóstico por imagem , Adolescente , Adulto , Bronquiectasia/diagnóstico por imagem , Broncografia , Criança , Pré-Escolar , Dilatação Patológica , Disautonomia Familiar/complicações , Disautonomia Familiar/epidemiologia , Disautonomia Familiar/fisiopatologia , Esôfago/patologia , Feminino , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Estudos Retrospectivos , Escoliose/complicações , Tomografia Computadorizada por Raios X , Adulto JovemAssuntos
Disautonomia Familiar , Adolescente , Adulto , Fatores Etários , Criança , Pré-Escolar , Disautonomia Familiar/diagnóstico , Disautonomia Familiar/epidemiologia , Disautonomia Familiar/genética , Disautonomia Familiar/fisiopatologia , Disautonomia Familiar/terapia , Feminino , Humanos , Lactente , Recém-Nascido , Testes de Inteligência , Masculino , Pessoa de Meia-Idade , Exame Neurológico , Fatores SexuaisRESUMO
STUDY OBJECTIVE: To determine the benefits of daily use of high-frequency chest wall oscillation (HFCWO) in familial dysautonomia (FD) patients with lung disease. DESIGN: Pulmonary function tests, chest radiographs, and blood tests were performed on entry to the study. A retrospective chart review of 12 months prior to entry provided baseline data regarding respiratory illnesses, medications, doctor visits, hospitalizations, and absenteeism. Daily logs provided prospective data on these parameters as well as HFCWO usage. Evaluations were performed at 1, 3, 6, 9, and 12 months for pulse oximetry, spirometry, and log review. At the exit evaluation, blood tests and chest radiographs were repeated. PATIENTS: Fifteen FD patients with history of lung disease requiring daily inhalation therapy (7 female and 8 male; age range, 11 to 33 years) were enrolled in a 1-year clinical trial of HFCWO therapy. Two subjects withdrew after 3 months and 6 months, respectively. Each individual served as his/her own control. RESULTS: Oxygen saturation improved by 1 month (median, 97.5%; interquartile range [IQR], 96 to 98%; vs median, 94%; IQR, 89 to 96%) and was sustained at exit evaluation (median, 98%; IQR, 98 to 98%) [p = 0.004]. Median FVC and peak expiratory flow rate (PEFR) were the pulmonary function measures with sustained improvement from baseline to exit (p = 0.02 and p = 0.03, respectively). When retrospective and prospective data were compared, all measured health outcomes improved significantly, including pneumonias (p = 0.0156), hospitalizations (p = 0.0161), antibiotic courses (p = 0.0005), antibiotic days (p = 0.0002), doctor visits (p = 0.0005), and absenteeism (p = 0.0002). CONCLUSION: In this limited study of FD patients, HFCWO effected significant improvements in all measured health outcomes and oxygen saturation; FVC and PEFR were the pulmonary function measures demonstrating sustained improvement.
Assuntos
Oscilação da Parede Torácica , Disautonomia Familiar/epidemiologia , Pneumopatias/terapia , Adolescente , Adulto , Criança , Feminino , Humanos , Pneumopatias/epidemiologia , Masculino , Oximetria , Oxigênio/sangue , Pico do Fluxo Expiratório , Estudos Prospectivos , Recidiva , Testes de Função Respiratória , Estudantes de Saúde Pública , Resultado do Tratamento , Capacidade VitalRESUMO
PURPOSE: Video-EEG in a family of three patients with slow development and familial dysautonomia demonstrated absence seizures associated with 3-Hz generalized spike-and-wave discharges. The seizures were refractory to antiepileptic drugs (AEDs). METHODS: Treatment was given with rice-based cereal electrolyte oral solution. RESULTS: Treatment induced seizure freedom and normalization of EEG in all three patients. Repeated video-EEG monitoring with discontinuation of AEDs and maintenance of the oral hydration therapy was associated with recurrence of epileptic activity. All three patients have remained seizure free (approximately 1 year) with a combination of topiramate and electrolytic therapy. CONCLUSIONS: Rice-based oral electrolyte hydration therapy may play a role in prevention and control of seizures in patients with familial dysautonomia.
Assuntos
Disautonomia Familiar/terapia , Eletrólitos/uso terapêutico , Epilepsia/terapia , Soluções para Reidratação/administração & dosagem , Anticonvulsivantes/uso terapêutico , Carboidratos/administração & dosagem , Citratos/administração & dosagem , Comorbidade , Disautonomia Familiar/epidemiologia , Eletrólitos/administração & dosagem , Epilepsia/tratamento farmacológico , Epilepsia/epidemiologia , Humanos , Oryza , Potássio/administração & dosagem , Sódio/administração & dosagem , Resultado do TratamentoRESUMO
Familial dysautonomia (FD) is an autosomal recessive disorder characterized by hereditary sensory and autonomic neuropathies. Although extremely rare in most populations, FD is common among Ashkenazi Jews (AJ), with a calculated carrier frequency of 1 in 30, based on disease prevalence. The gene for FD was recently identified as IKBKAP. One major mutation (IVS2 + 6T --> C) is responsible in >99.5% of cases among AJ. The purpose of this study was to determine the actual frequency of FD carriers in the AJ population in Israel and to determine whether carriers are more frequent among a subpopulation of AJ from Poland. The study group included 1267 Jews of Ashkenazi origin who were referred for routine DNA screening tests. These included 1100 individuals who were full AJ and 167 who were part AJ. None had a family history of FD. Mutation analysis for (IVS2 + 6T --> C) was performed by PCR amplification followed by restriction enzyme analysis. All positive cases were confirmed by DHPLC WAVE( trade mark ). Among the 1100 full AJ tested, 34 were found to be FD carriers (1:32). The incidence of mutation carriers was significantly higher in AJ of Polish descent (1:18) compared to AJ of non-Polish descent (1:99). Among the 167 individuals who were part AJ, there were 3 carriers (1:56). The incidence of FD among AJ, particularly those of Polish background, warrants population screening. Population screening may be performed by denaturing high-performance liquid chromatography.
Assuntos
Disautonomia Familiar/epidemiologia , Disautonomia Familiar/genética , Judeus/genética , Sequência de Bases , Cromatografia Líquida de Alta Pressão , Análise Mutacional de DNA , Primers do DNA/genética , Feminino , Triagem de Portadores Genéticos , Testes Genéticos , Humanos , Israel/epidemiologia , Masculino , Polônia/etnologia , Reação em Cadeia da PolimeraseAssuntos
Doenças em Gêmeos/epidemiologia , Disautonomia Familiar/epidemiologia , Epilepsia Tipo Ausência/epidemiologia , Criança , Comorbidade , Doenças em Gêmeos/genética , Disautonomia Familiar/diagnóstico , Disautonomia Familiar/genética , Eletroencefalografia/métodos , Epilepsia Tipo Ausência/diagnóstico , Epilepsia Tipo Ausência/genética , Humanos , Judeus/genética , Masculino , Monitorização Fisiológica , Exame Neurológico , Gêmeos Monozigóticos/genética , Gravação de VideoteipeRESUMO
Familial dysautonomia (FD) is an autosomal recessive congenital neuropathy that occurs almost exclusively in the Ashkenazi Jewish (AJ) population. Mutations in the IkappaB kinase complex-associated protein (IKBKAP) gene cause FD. Two IKBKAP mutations, IVS20(+6T --> C) and R696P, have been identified in FD patients of AJ descent. The splice site mutation IVS20(+6T --> C) is responsible for > 99.5% of known AJ patients with FD, and haplotype analyses were consistent with a common founder. In contrast, the R696P mutation has been identified in only a few AJ patients. To facilitate carrier detection, a single PCR and allele-specific oligonucleotide (ASO) hybridization assay was developed to facilitate the detection of both the IVS20(+6T --> C) and R696P mutations. Screening of 2,518 anonymous AJ individuals from the New York metropolitan area revealed a carrier frequency for IVS20(+6T --> C) of 1 in 32 (3.2%; 95% CI, 2.5-3.9%), similar to the previously estimated carrier frequency (3.3%) based on disease incidence. No carrier was identified for the R696P lesion, indicating that the mutation was rare in this population (< 1 in 2,500). This sensitive and specific assay should facilitate carrier screening for FD mutations in the AJ community, as well as postnatal diagnostic testing.
Assuntos
Proteínas de Transporte/genética , Disautonomia Familiar/genética , Judeus/genética , Processamento Alternativo/genética , DNA/genética , Disautonomia Familiar/epidemiologia , Frequência do Gene , Testes Genéticos , Heterozigoto , Mutação , Mutação de Sentido Incorreto , New York/epidemiologia , Reação em Cadeia da Polimerase , Fatores de Elongação da TranscriçãoRESUMO
Familial dysautonomia (DYS), the Riley-Day syndrome, is an autosomal recessive disorder characterized by developmental loss of neurons from the sensory and autonomic nervous system. It is limited to the Ashkenazi Jewish population, where the carrier frequency is 1 in 30. We have mapped the DYS gene to chromosome 9q31-q33 by linkage with ten DNA markers in 26 families. The maximum lod score of 21.1 with no recombinants was achieved with D9S58. This marker also showed strong linkage disequilibrium with DYS, with one allele present on 73% of affected chromosomes compared to 5.4% of controls (chi 2 = 3142, 15 d.f. p < 0.0001). D9S53 and D9S105 represent the closest flanking markers for the disease gene. This localization will permit prenatal diagnosis of DYS in affected families and aid the isolation of the disease gene.
Assuntos
Cromossomos Humanos Par 9 , Disautonomia Familiar/genética , Marcadores Genéticos , Polimorfismo Genético , Alelos , Mapeamento Cromossômico , Disautonomia Familiar/diagnóstico , Disautonomia Familiar/epidemiologia , Disautonomia Familiar/etnologia , Feminino , Doenças Fetais/diagnóstico , Doenças Fetais/genética , Frequência do Gene , Genes Recessivos , Triagem de Portadores Genéticos , Humanos , Incidência , Judeus/genética , Desequilíbrio de Ligação , Escore Lod , Masculino , Linhagem , Reação em Cadeia da Polimerase , Polimorfismo de Fragmento de Restrição , Diagnóstico Pré-NatalAssuntos
Disautonomia Familiar/epidemiologia , Grupos de Autoajuda , Adulto , Canadá , Criança , Humanos , PesquisaRESUMO
The incidence of all diagnosed cases of familial dysautonomia in Israel among Ashkenazi Jews from 1977-1981 was 27/100,000 or 1/3703. This incidence is higher than that previously reported in Israel in 1967 or 8.3/100,000 (1/12,048) (Moses et al. 1967). It is also higher than that of North American Ashkenazi Jews in 1970, when the rate was 5-10/100,000 (1/10,000-20,000) (Brunt & McKusick 1970). This higher incidence could be explained by current awareness of the diagnosis, or by the emergence of more cases.